Real Breakthroughs
This content is for members
Merck (MRK)
Let’s Go Shopping
In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did …
Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca
This content is for members
Merck’s Good News. Checkpoint Inhibitors’ Revenues
This content is for members
The Week in Review
This content is for members
Tracing Large Pharmaceutical Companies’ Choices
This content is for members
KalVista Pharmaceuticals Signs a Lucrative Strategic Agreement with Merck
– The Agreement Covers the Development of Investigational Plasma Kallikrein Inhibitors for Diabetic Macular Edema (DME) – Upfront Fee ($37 …
Prohost Letter #413
This content is for members
Some Small Outperforming Biotech Firms
This content is for members
NewLinK Genetics: A Rally Is Recuperating NLNK’s Unwarranted Stock Losses
Indeed, updated data from the ongoing Phase 2 NLG2103 study of NewLink Genetics (NLNK) IDO inhibitor immunotherapy product indoximod in combination with the …
Prohost Letter #412 Part 3
This content is for members
Targeted Drugs That Would Improve on Immunotherapy Treatments’ Outcomes. See Array and Exelixis
This content is for members
Merck’s Keytruda: Extremely Valuable, But Not for Multiple Myeloma
Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair to say that this checkpoint inhibitor drug will …
Prohost Letter #411
This content is for members
Prohost Letter #410
This content is for members